Elefante Mark B bought a new position in Merck KGaA (OTCMKTS:MKGAF – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 4,800 shares of the company’s stock, valued at approximately $617,000.
Several other hedge funds have also modified their holdings of MKGAF. Barrow Hanley Mewhinney & Strauss LLC purchased a new position in Merck KGaA in the 2nd quarter worth approximately $942,087,000. Bank of Nova Scotia acquired a new position in shares of Merck KGaA during the second quarter worth $281,696,000. Danske Bank A S purchased a new position in shares of Merck KGaA in the second quarter valued at $276,535,000. Korea Investment CORP acquired a new stake in Merck KGaA during the 2nd quarter valued at $239,191,000. Finally, Great Lakes Advisors LLC purchased a new stake in Merck KGaA during the 2nd quarter worth $183,444,000. 0.10% of the stock is currently owned by hedge funds and other institutional investors.
Merck KGaA Stock Performance
OTCMKTS:MKGAF opened at $163.21 on Monday. The firm has a 50-day moving average of $162.62 and a two-hundred day moving average of $148.44. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.31 and a quick ratio of 0.84. The stock has a market cap of $21.09 billion, a P/E ratio of 24.92 and a beta of 0.96. Merck KGaA has a 1-year low of $116.68 and a 1-year high of $175.56.
Merck KGaA Company Profile
Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.
The company’s operations are organized mainly into three businesses.
Featured Articles
- Five stocks we like better than Merck KGaA
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Want to see what other hedge funds are holding MKGAF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck KGaA (OTCMKTS:MKGAF – Free Report).
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
